OPEN CLINICAL TRIALS

NCT06225596

Bicycle BT8009-230 DURAVELO-2

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06112379

AstraZeneca D926QC00001 TROPION-04

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (TROPION-Breast04)

NCT05774951

AstraZeneca D8531C00002 CAMBRIA-1

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05633654

Gilead GS-US-595-6184 ASCENT

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer that have Residual Disease After Surgery and Neoadjuvant Therapy

NCT06065748

Genentech CO44657 pionERA

A Phase III, Randomized, Open-Label Study of Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant both Combined with a CDK 4/6 Inhibitor, In patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

NCT05296798

Genentech WO43571 heredERA

A Phase Ill, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy With Phesgo+Taxane in Patients with Previously Untreated HER2-Positive Estrogen Receptor-Positive

NCT05501886

Celcuity CELC-G-301 VIKTORIA1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

NCT06103864

AstraZeneca D7630C00001 TROPION-05

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06252649

Amgen 20210081 CodeBreaK301

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With our Without Bevacizumab-awwb for Treatment-na·ive Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT05211895

AstraZeneca D9075C00001 PACIFIC-8

A Phase Ill, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB1 54) in Participants with Locally Advanced (Stage Ill), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

NCT05899608

Summit SMT112-3003 HARMONi-3

A Randomized, Controlled, Multiregional Phase 3 Study of lvonescimab Combined with Chemotherapy Versus Pembrolizumab Combined for the first-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer

NCT05555732

Daiichi Sankyo DS1062-A-U303 TROPION-LUNG07

A Randomized Phase 3 Study of Datopotamab Deruxtecan (DatoDXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or metastatic PD-L 1 TPS<50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG07)

NCT04613596

Mirati 849-007 KRYSTAL-7

"A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation ••open for Phase Ill (TPS ≥ 50%)"

NCT04042701

Daiichi Sankyo DS8201-A-U106

A Phase 1 b, Multicenter, two-part, open-label study of trastuzumab deruxtecan, an anti-human epidermal growth factor receptor-2 (HER2)- antibody drug conjugate (ADC), in combination with pembrolizumab, an anti-PD-1 antibody, in subjects with locally advanced/metastatic breast or non-small cell lung cancer (NSCLC) **currently enrolling in Cohort 3 (NSCLC)

NCT06497556

Genentech BO45217 KRASCENDO-1

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib versus Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT05353257

Shanghai Henlius HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase Ill Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

NCT05468489

Shanghai Henlius HLX10-005-SCLC301-E ASTRIDE

A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05578976

AbbVie M20-621 EPCORE DLBCL-2

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT06191744

AbbVie M22-003 EPCORE FL-2

A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Evaluate the Safety and Efficacy of Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

NCT05952024

AstraZeneca D8227C00002 ACRUE

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

NCT05451810

AbbVie M23-362

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting

NCT04224493

Epizyme EZH-302 SYMPHONY-1

"A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituxumab in Subjects with Relapsed/Refractory Follicular Lymphoma **Stage 1 - cannot participate due to PKs **Stage 2 - open to enrollment"

NCT06158841

AbbVie M22-574 CERVINO

A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

NCT03110822

Oncotherapeutics I-RUX-15-04

"A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients **Parts 3 and 4 - open to enrollment **Parts 1 and 2 - closed to enrollment"

NCT05939414

Novartis CAAA617D12302 PSMA-DC

An International, Prospective, Open-label, Multi-center, Randomized, Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)

NCT04657068

Artios ART0380C001 REFMAL 721

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

NCT04919811

Daiichi Sankyo DS8201-A-U106

"A Phase 1 b, Multicenter, two-part, open-label study of trastuzumab deruxtecan, an anti-human epidermal growth factor receptor-2 (HER2)- antibody drug conjugate (ADC), in combination with pembrolizumab, an anti-PD-1 antibody, in subjects with locally advanced/metastatic breast or non-small cell lung cancer (NSCLC) **currently enrolling in Cohort 3 (NSCLC)"

NCT06005974

Recursion REC-4881-221

A Phase 2, Open-Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation

NCT02912949

Merus MCLA-128-CL01

A phase I/II study of MCLA-128, a full length lgG1 Bispecific Antibody Targeting HER2 and HER3 in Patients with Solid Tumors

CSNF is part of The TIME Trial Program, a just-in-time network of providers that supports rapid patient identification, site activation, and enrollment of select clinical trials. Building off of existing relationships with a large network of community hospitals and practices, TIME activates clinical trials at pre-qualified sites in its network in an average of 10 days, bringing the very best clinical trials to community centric parts of this country and giving access to thousands of patients that have historically been denied novel therapeutics. As part of The TIME Trial Network, CSNF has access to the biggest marketplace of trials that can be quickly initiated when there is a patient on-site that is ready to enroll. The program's just-in-time model allows for both sites and sponsors to locate extremely rare patients and then open a trial specifically on that patient’s behalf in a fraction of the time it typically takes.